Ribavirin in respiratory syncytial virus infection

Randomised trials and ribavirin

‘Uncertainty’ about whether to use a treatment is the basis of all randomised controlled trials. Indeed, it can be argued that it is unethical not to randomise when there is uncertainty because this ensures that only 50% of current patients will receive whichever turns out to be the worse management, quite apart from the benefits which accrue to those who have the illness in the future.

Should paediatricians be uncertain whether or not to use ribavirin? The articles on the previous pages certainly suggest that there are widely varying beliefs about the place of this new drug in everyday practice, and variations in practice are a measure of ‘collective’ uncertainty. Individually, paediatricians should decide by critically appraising the evidence which is in the public domain for themselves. (There are understandable commercial and other reasons why a company may choose not to publish data about a new product, but Dr Snell must recognise that these data cannot then be used as ‘public’ support for the product). Most weight should be given to the randomised controlled trials. The weakness of using historical controls is illustrated by the apparent change over time in the risk of death due to respiratory syncytial virus in infants with congenital heart disease treated conservatively. Comparisons using concurrent but non-randomised controls are also highly prone to bias. The five properly reported randomised controlled trials included only 76 children treated with ribavirin. They are ‘efficacy’ or ‘explanatory’ (can it work?) trials. That is to say, small numbers of patients were investigated in a tightly controlled environment and outcome was assessed by short term surrogate measures such as illness severity scores and arterial oxygen concentrations. These trials do suggest a benefit in these respects, but the clinical significance of this is unclear, particularly in the longer term. Dr Isaacs and his colleagues (p 986) call for a much larger ‘effectiveness’ or ‘pragmatic’ (does it work?) trial to assess ribavirin in everyday practice in terms of clinically more meaningful outcomes such as length of time on a ventilator and length of stay in hospital. Improvement in these terms could offset the high financial cost of treatment.

The possibility of unanticipated adverse effects of ribavirin must also be included in the appraisal. It is reassuring that licensing authorities in the United Kingdom and the United States have given ribavirin a (limited) licence, because these authorities are primarily concerned with drug safety. Nevertheless, the Committee on Safety of Medicines has made special reporting a requirement for ribavirin and the marketing data sheet does mention the possibility of serious side effects in the short term. Furthermore, larger numbers of children must be followed up for much longer before rare, but serious, long term adverse effects can be ruled out with any confidence.

On the basis of the limited evidence currently available paediatricians are likely to come to differing conclusions about the effectiveness and safety of ribavirin. Some may feel that ribavirin must be used in some clinical situations; others may conclude that on present evidence, it has no place in everyday practice. But I suspect that many will remain uncertain whether they should use ribavirin for respiratory syncytial virus infection, even for children who are most severely affected or most at risk. If so, this uncertainty can only be resolved by large ‘pragmatic’ randomised controlled trials as called for by Dr Isaacs and his colleagues.

Adrian Grant
Epidemiologist
National Perinatal Epidemiology Unit,
Radcliffe Infirmary,
Oxford OX2 6HE.

Response

Dr Snell reaches different figures from us on the number of children who have received ribavirin in controlled trials because of our different interpretation of what constitutes a quotable controlled trial. But this is quibbling: our point was that thousands have been treated on the basis of relatively little controlled data. To use the granting of a product licence by licensing authorities as evidence of efficacy is novel but scientifically unacceptable.

We do not believe that Dr Snell has refuted our three main points, namely that there is no evidence...